SCI答复审稿人的回信技巧

SCI答复审稿人的回信技巧一篇稿子从酝酿到成型历经艰辛，投出去之后又是漫长的等待，好容易收到编辑的回信，得 到的往往又是审稿人不留情面的一顿狂批。这时候，如何有策略有技巧的回复审稿人就显得 尤为重要。好的回复是文章被接收的重要砝码，而不恰当的回复轻则导致再次修改从而拖延 发稿时间，重则导致文章被拒，前功尽弃。下面把我平时总结的一些答复审稿人的策略和写 回复信的格式和技巧跟大家交流一下。首先，绝对服从编辑的意见。在审稿人给出各自的意见之后，编辑一般不会再提出自己的意 见。但是，编辑一旦提出某些意见，就意味着他认为这是文章里的重大缺陷，至少是不合他 的口味。这时，我们唯一能够做的只能是服从。因为毕竟是人家掌握着生杀予夺的大权。第二，永远不要跟审稿人争执。跟审稿人起争执是非常不明智的一件事情。审稿人意见如果 正确那就不用说了，直接照办就是。如果不正确的话，也大可不必在回复中冷嘲热讽，心平 气和的说明白就是了。大家都是青年人，血气方刚，被人拍了当然不爽，被人错拍了就更不 爽了。尤其是一些名门正派里的弟子，看到一审结果是major而不是minor本来就已经很不 爽了，难得抓住审稿人的尾巴，恨不得拖出来打死。有次审稿，一个审稿人给的意见是增加 两篇参考文献（估计也就是审稿人自己的文章啦），结果作者在回复中写到，making a reference is not charity!看到之后我当时就笑喷了，可以想象审稿人得被噎成什么样。正如 大家所想的那样，这篇稿子理所当然的被拒了，虽然后来经编辑调解改成了 major revision， 但毕竟耽误的是作者自己的时间不是？第三，合理掌握修改和argue的分寸。所谓修改就是对文章内容进行的修改和补充，所谓argue 就是在回复信中对审稿人的答复。这其中大有文章可做，中心思想就是容易改的照改，不容 易改的或者不想改的跟审稿人argue。对于语法、拼写错误、某些词汇的更换、对某些公式 和图表做进一步解释等相对容易做到的修改，一定要一毫不差的根据审稿意见照做。而对于 新意不足、创新性不够这类根本没法改的，还有诸如跟算法A，B，C，D做比较，补充大 量实验等短时间内根本没法完成的任务，我们则要有理有据的argue。在Argue的时候首先 要肯定审稿人说的很对，他提出的方法也很好，但本文的重点是blablabla,跟他说的不是一 回事。然后为了表示对审稿人的尊重，象征性的在文中加上一段这方面的discussion，这样 既照顾到了审稿人的面子，编辑那也能交待的过去。第四，聪明的掌握修改时间。拿到审稿意见，如果是m inor，意见只有寥寥数行，那当然会 情不自禁的一蹴而就，一天甚至几小时搞定修改稿。这时候，问题在于要不要马上投回去了？ 我的意见是放一放，多看一看，两个星期之后再投出去。这样首先避免了由于大喜过望而没 能及时检查出的小毛病，还不会让编辑觉得你是在敷衍他。如果结果是major，建议至少放 一个月再投出去，显得比较郑重。上面是一些一般性的答复审稿人的策略，在实际中的应用还需要大家见仁见智。下面谈谈答 复信的写法。写答复信的唯一目的是让编辑和审稿人一目了然的知道我们做了哪些修改。因此，所有的格 式和写法都要围绕这一目的。一般来说可以把答复信分成三部分，即List of Actions, Responses to Editor, Responses to Reviewers。第一部分 List of Actions 的作用是简明扼要的列 出所有修改的条目，让编辑和审稿人在第一时间对修改量有个概念，同时它还充当着修改目 录的作用，详见下面的例子。剩下的两部分是分别对编辑和审稿人所做的答复，格式可以一 样，按照“意见”一“argue”（如果有的话）一“修改”这样逐条进行。清楚醒目起见，可以用不 同字体分别标出，比如“意见”用italic, “argue”正常字体，“修改”用bold。下面举例说明各 部分的写法和格式。编辑意见：请在修改稿中用双倍行距。审稿人1：意见1：置疑文章的创新性，提出相似的工作已经被A和B做过。意见2：算法表述不明确。意见3：对图3的图例应做出解释。审稿人2：意见1：图2太小。意见2：第3页有个错别字。很显然，根据上面的答复策略，我们准备对除1号审稿人意见1之外的所有意见进行相应改 动，而对1.1采取argue为主的策略。答复如下：List of ActionsL0A1: The revised manuscript is double spaced.L0A2: A discussion on novelty of this work and a comparison with A and B have been added in page 3.LOA3: A paragraph has been added in page 5 to further explain the algorithm *.LOA4: Explanations of the legend of Figure 3 have been added in page 7.LOA5: Figure 2 has been enlarged.LOA6: All typos have been removed.=分页=Responses to Editor请在修改稿中用双倍行距。We have double spaced the text throughout the revised manuscript, see LOA1. =分页=Responses to ReviewersTo Reviewer 1:意见1：置疑文章的创新性，提出相似的工作已经被A和B做过。Thank you for pointing this out. A and Bs research groups have done blablablabla. However, the focus of our work is on blablablabla, which is very different from A and Bs work, and this is also the major contribution of our work. We have added the following discussion on this issue in our revised manuscript, see LOA2.“blablablabla（此处把A和B的工作做一个review，并提出自己工作和他们的区别之处）” 意见2：算法表述不明确。We have added the following discussion to further explain algorithm *, see LOA3. “blablablabla （此处进一步解释该算法）”意见3：对图3的图例应做出解释。We have added the following explanations of the legend of Figure 3, see LOA3.“blablablabla （图3图例的解释）”=分页=To Reviewer 2:意见1：图2太小。We have enlarged Figure 2, see LOA 4.意见2：第3页有个错别字。We have removed all typos, see LOA5.=分页=总之，写答复信的宗旨就是用最少的时间和工作量达到论文被接收的目的。这里权当是抛砖 引玉，希望和大家多多交流。来源：pitlord999小木虫如何回复SCI投稿审稿人意见如何回复 SCI 投稿审稿人意见(1)1. 所有问题必须逐条回答。2. 尽量满足意见中需要补充的实验。3. 满足不了的也不要回避，说明不能做的合理理由。4. 审稿人推荐的文献一定要引用，并讨论透彻。以下是本人对审稿人意见的回复一例，仅供参考。续两点经验：1，最重要的是逐条回答，即使你答不了，也要老实交代；不要太狡猾，以至于耽误事；2，绝大部分实验是不要真追加的，除非你受到启发，而想该投另外高档杂志因为你既然已经写成文章，从逻辑上肯定是一个完整的 “story” 了。以上指国际杂志修稿。国内杂志太多，以至于稿源吃紧，基本没有退稿，所以你怎么修都是 接受。我的文章水平都不高，主要是没有明显的创新性，也很苦恼。但是除了开始几篇投在国内杂 志外，其他都在国际杂志（也都是SCI）发表。以我了解的情况，我单位其他同志给国内杂 志投稿，退稿的极少，只有一次被某某科学进展拒绝。究其原因，除了我上面说的，另 外可能是我单位写稿子还是比较严肃，导师把关也比较严的缘故。自我感觉总结（不一定对）：1）国内杂志审稿极慢（少数除外），但现在也有加快趋势；2）国内杂志编辑人员认真负责的人不多，稿子寄去后，少则几个月，多则一年多没有任何 消息；3）国内杂志要求修改的稿子，如果你自己不修，他最后也给你发；4）国外杂志要求补充实验的，我均以解释而过关，原因见少帖）。还因为：很少杂志编辑把 你的修改稿再寄给当初审稿人的，除非审稿人特别请求。编辑不一定懂你的东西，他只是看 到你认真修改，回答疑问了，也就接受了（当然高档杂志可能不是这样，我的经验只限定一 般杂志（影响因子1-5 ） 。欢迎大家批评指正。我常用的回复格式，呵呵。Dear reviewer:I am very grateful to your comments for the manuscript. According with your advice, we amended the relevant part in manuscript. Some of your questions were answered below.1）2）引用审稿人推荐的文献的确是很重要的，要想办法和自己的文章有机地结合起来。至于实验 大部分都可以不用补做，关键是你要让审稿人明白你的文章的重点是什么，这个实验对你要 强调的重点内容不是很必要，或者你现在所用的方法已经可以达到目的就行了。最后要注意， 审稿人也会犯错误，不仅仅是笔误也有专业知识上的错误，因为编辑找的审稿人未必是你这 个领域的专家。只要自己是正确的就要坚持。在回复中委婉地表达一下你的意见，不过要注 意商讨语气哦！我得回复格式是这样的：Dear Professor xx:Thank you very much for your letter dated xxx xx xxxx, and the referes reports. Based on your comment and request, we have made extensive modification on the original manuscript. Here, we attached revised manuscript. in the formats of both PDF and MS word, for your approval. A document answering every question from the referees was also summarized and enclosed. A revised manuscript. with the correction sections red marked was attached as the supplemental material and for easy check/editing purpose. Should you have any questions, please contact us without hesitate.然后再附上Q/A,基本上嘱条回答，写的越多越好(老师语)。结果修改一次就接收了：我的回复，请老外帮忙修改了Dear Editor:Thank you for your kind letter of “” on November *, 2005. We revised the manuscript.in accordance with the reviewers comments, and carefully proof -read the manuscript. to minimize typographical, grammatical, and bibliographical errors.Here below is our description on revision according to the reviewers comments. Part A (Reviewer 1). The reviewers comment: The authors Answer: 2. The reviewers comment: The authors Answer: Part B(Reviewer 2)1. The reviewers comment: The authors Answer: 2. The reviewers comment: The authors Answer: Many grammatical or typographical errors have been revised.All the lines and pages indicated above are in the revised manuscript.Thank you and all the reviewers for the kind advice.Sincerely yours,*精华如何回复 SCI 投稿审稿人意见(2)一个回复的例子(已接收)Major comments:1. The authors need to strengthen their results by including MMP secretion, and tran-matrigel migration by a positive control progenitor cell population i.e. enriched human CD34 cells obtained from mobilized PBL, since this is a more clinically relevant source of CD34 cells which has also been shown to secrete both MMP-9 and MMP-2 (ref. 11). CD34 enriched cells from steady state peripheral blood which also secrete MMPs are also of interest.2. In fig1Cplease specify which cell line represents MMP-negative cells. This needs to be clarified, as well as a better explanation of the method of the protocol.3. The ELISA results are represented as fold increase compared to control. Instead, we suggest that standards should be used and results should be presented as absolute concentrations and only then can these results be compared to those of the zymography.4. When discussing the results, the authors should distinguish clearly between spontaneous migration vs chemotactic migration.Furthermore, the high spontaneous migration obtained with cord blood CD34 cells should be compared to mobilized PBL CD34 enriched cells and discussed.5. The authors claim that the clonogenic assay was performed to determine the optimum concentration for inhibition of MMP activity by phenanthroline and anti MMP-9 mAb, however they should clarify that this assay can only determine the toxicity of the inhibitors and not their optimal inhibitory concentrations.Minor comments: 1. There are many spelling and syntax errors, especially in the results and discussion, which need correction.a. Of special importance, is the percent inhibition of migration,which is described as percent of migration. i.e. pg 7:Migration of CB CD34 was reduced to 73.3%? Instead should read Migration of CB CD34 was reduced by 73.3%?b. The degree symbol needs to be added to the numbers in Materials and methods.2. It would be preferable to combine figure1Aand B, in order to confirm the reliability of fig. 1B by a positive control (HT1080).Answer to referee 1 comment:1. Mobilized peripheral blood is a more clinical source of CD34+ cells, so it is necessary to compare the MMP-9 secretion and trans-migration ability of CB CD34+ cells with that of mobilized PB CD34+ cells. However, we couldnt obtain enough mobilized PB to separate PB CD34+ cells and determine the MMP-9 secretion and migration ability, so we couldnt complement the study on PB CD34+ cells in this paper. Results obtained by Janowska-Wieczorek et al found that mobilized CD34+ cells in peripheral blood express MMP-9. Furthermore, Domenechs studyshowed that MMP-9 secretion is involved in G-CSF induced HPC mobilization. Their conclusions have been added in the discussion. In our present study, our central conclusion from our data is that freshly isolated CD34+ stem/progenitor cells obtained from CB produce MMP-9.2. MMP-9 negative cell used in fig1Cwas Jurkat cell. In zymographic analysis, MMP-9 was not detected in the medium conditioned by Jurkat cell. To exclude that the contaminating cells may play a role in the observed MMP-9 production, we screened the media conditioned by different proportion of CB mononuclear cells with MMP-9 negative cells by zymography. This result may be confusion. Actually, only by detecting the medium conditioned by 2X105 CB mononuclear cells (MNC)/ml (since the purities of CD34+ cell are more than 90%), it could exclude the MNC role. In the revised manuscript, we only detected MMP-9 activity and antigen level in the medium conditioned by 2X105 CB mononuclear cells (MNC)/ml. There is no MMP-9 secretion be detected in the medium conditioned by 2X105 CB MNC/ml. It excluded the possibility that the MMP-9 activity in CB CD34+ cells conditioned medium is due to the contamination by MNC.3.In this revised paper, we have detected the MMP-9 antigen levels by using commercial specific ELISA kits (R&D System, sensitivity, 0.156ng/ml). Recombinant MMP-9 from R&D System was used as a standard. The results are expressed in the absolute concentration. The absolute concentration result has been added in the paper. As shown in Fig2, MMP-9 levels were detectable in both CB CD34+ cell conditioned medium and BM CD34+ cell conditioned medium. However, MMP-9 level was significantly higher in CB CD34+ cell conditioned medium than in BM CD34+ cell conditioned medium (0.4060.133ng/ml versus 0.1950.023ng/ml). Although gelatinolytic activity was not detected in media conditioned by CD34+ cells from BM, sensitivity of ELISA favors the detection of MMP-9 antigen in the BM CD34+.4. In our study, to establish the direct link between MMP-9 and CB CD34+ cells migration, we only determined the role of MMP-9 inspontaneous migration of CB CD34+ cells, but not in chemotactic migration. Actually, regulation of hematopoietic stem cell migration, homing and anchorage of repopulation cells to the bone marrow involves a complex interplay between adhesion molecules, chemokines, cytokines and proteolytic enzymes. Results obtained by the groups of Voermans reveal that not only the spontaneous migration but also the SDF-1 induced migration of CB CD34+ cells is greatly increased in comparison to CD34+ cells from BM and peripheral blood.5. CD34+ cells we obtained in each cord blood sample were very limited. It is not enough to screen the inhibitors concentrations to select the optimal inhibitory concentrations. In the blocking experiments, based on the concentrations used by others and the manufacturers recommendation, we then determined the inhibitors concentrations by excluding the toxicity of the inhibitors in that concentration, which was determined by clonogenic assay.Minor comments:1.The spelling and syntax errors have been checked and corrected.2.Since the results in figure1Aand B were obtained from two separated and parallel experiments, it is not fitness to combine two figures.这是我的一篇修稿回复，杂志是JBMR-A,影响因子3.652,已发表，供参考！Reply to the comments on JBMR-A-05-0172Comment:Reference #10 is missing from the Introduction but used much later in the manuscript. Should these be in order used in manuscript?Reply:The missing reference has been added into the revised manuscript.Comment (continued):What is the sample size for all tests performed?Reply:The sample size for drug release and PCL degradation tests was 3.0x3.0 cm2, with a thickness of about0.1mmand a weight of about 40mg. This dada have been added into the revised manuscript.Comment (continued):Figure 7. There is no scientific evidence presented in the TEM figure to convince this reviewer of sub-jets. This statement on Page 9 cannot be made without clear evidence during the jet formation/separation. Figure 7 is just a large fiber and small fiber fused together, no other conclusion than this can be made.Reply:Necessary change in the statements has been made in the revised manuscript. as well as in the referred figure accordingly.Comment (continued):Table 3: Need standard deviation for all values reported not just for a select few.Equation after Table 3 not necessary. Just reference method used.Reply:Done accordingly.Comment (continued):Page 11: faster weight loss What was the sample size? Where is the statistical analysis of this data? This reviewer does not see a significant difference in any of the data presented, thus weight loss would be considered equivalent.Reply:Although not too much difference was seen, the conclusion that “the GS/PCL membrane exhibited a relatively faster weight loss compared with the RT/PCL membrane” was indeed applicable through “one-way analysis of variance (ANOVA)” analysis. Following the reviewers comment, a new sub-section has been added to the manuscript. to address the statistical analysis for the data.Page 12: What is the sample size for release data? Looks like results based on a sample size of one? Need stand deviations on the data presented in Figure 11. Why wasnt release performed and compared for all electrospun conditions investigated otherwise?Reply:Three repeated tests were performed for each set of measurements and the resulting data were averaged. As stated in the revised manuscript, each sample had a square area of 33cm2 with a slightly different thickness.Standard deviations have been added to the data shown in Fig. 11.The present manuscript. aimed to show that medical drugs can be encapsulated in ultrafine fibers through a co-axial electrospinning process. The drug release data intended to show that the encapsulation was successful. We did not consider any specific application in this preliminary paper, and in fact the two drugs were just chosen as model illustration. As such, there seemed not necessary to perform. release experiments for all of the membranes electrospun with different conditions (i.e. the core concentrations)Comment (continued):Table 3: Yangs or Youngs Modulus (page 10 says Youngs).Reply:Corrected accordingly.Comment (continued):Figure 11: What is the % release, not just concentration. Why just this small sample of release data? Where is the release data for the other conditions?Reply:Unfortunately, we did not measure the amount of the shell material in obtaining the composite nanofibers. Namely, the flow rate of the shell solution during the electrospinning was not accurately controlled using an injecting pump. Hence the % release was not applicable. Please refer to the previous reply related to Page 12 and Figure 11 for the remaining comments.We acknowledge the reviewers comments and suggestions very much, which are valuable in improving the quality of our manuscript.SCI 生物医学英文论文发表成功经验发表成功经验SCI 生物医学英文论文发表成功经验共享系列一-(Clinical Chemistry) 将自己近10年的科研工作中有关论文整理总结发表方面的一些信息贡献出来，与大家共享！ 如有时间，我拟将一些已经发表的文章，按照撰写与发表的实际经历与过程，即通过案例分 析每一个杂志的特色，审稿偏好review意见及答复要点等逐一分析。可能包含的杂志系 列有：nature methods, clinical chemistry，analytical chemistry，J. Clin. Immuno Biomed. Microdev， Front. Biosci， Mol. Cell. Biochem， J. Expert， Rev. Proteomics， J biochemistry本章先讲解美国Clinical Chemistry杂志，一个临床化学界的王牌杂志，近年其影响因子逐 年攀升，现为7.7分。Clinical Chemistry由美国AACC每月出版，接受的文章包括与人体疾 病相关的实验室研究，分析与分子诊断，仪器，资料处理，数据分析，临床研究等投稿dSSN： 0009-9147 网络版 ISSN： 1530-8561URL】 http:/intl.clinchem.org/镜像 URL】 http:/www.clinchem.org/出版者】 American Association for Clinical Chemistry (AACC)收费情况】 免费 , 全文内容简介】Clinical Chemistry is an international journal of laboratory medicine and molecular diagnostics.Clinical Chemistry - This highly respected and often-cited scientific journal is published monthly and contains peer-reviewed methodology, research papers and other articles relevant to clinical chemistry and related laboratory sciences. Its circulation is more than 15,000.David E. Bruns, MD, Editor, (Charlottesville Office)dbrunsclinchem.aacc.orgSandra Weaver, Senior Editorial Assistantsweaverclinchem.aacc.orgDonna Brandl, Editorial Assistantdbrandlclinchem.aacc.orgShane P. Cyr, Editorial Assistantscyrclinchem.aacc.orgMac Fancher, Publisher, (WashingtonOffice)mfancheraacc.orgMiriam Gonzalez, Publications Coordinatormgonzalezaacc.org【目录、摘要或全文上网等情况】Free TOC, 1965 -Free Abstract, 1975 -Free Fulltext, 1997 -1999Fulltext, 1997 -【杂志被索引的情况】Indexed in Chemical Abstracts.【备注】For faster access to Clinical Chemistry Online from these countries use this URL:http:/intl.clinchem.orqAustralia, Brazil, China, France, Germany, Hong Kong, Ireland, Israel, Italy, Japan, Mexico,Russia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, The Netherlands, UK 该杂志是由美国临床化学协会( American Association for Clinical Chemistry, AACC)主办的，于1948年成立，总部位于华盛顿，拥 有1万余会员。先在网站注册，登记，按照提示一步步提供文章名称，摘要，作者姓名，所 属领域，关键词，主文，图表等等。转换为 PDF 后就可以提交，然后给你一个查询号，接 着就是等待了。等了 20 多天，查阅状态看到了第一次回信：Home Author Area Reviewer Area Personal Info. ClinChem Home Sign Out Submit New Manuscript. Information for Authors Queue Summary Feedback Help FAQDecision Letter Return to QueueTo:作者姓名（电子邮件）From: clinchemedclinchem.aacc.orgSubject: Clinical Chemistry - Manuscript. DecisionCc:RE: Clinical Chemistry MS ID# CLINCHEM/2002/TITLE:Dear Dr. xxx:Your manuscript. has been examined by two expert reviewers. Please visit http:/submit.clinchem.orq to view their comments. For the reasons detailed in these comments, we cannot accept this manuscript. for publication in Clinical Chemistry in this form. Also, your Reference 28 is not formatted properly. Our Information for Authors will offer assistance with journal style; it can be found athttp:/www.aacc.orq/ccj/infoauth.stmWe would consider a revised version that takes these criticisms into account. If you should resubmit the paper I would also ask that you have several English speaking colleagues proof the paper for grammar and composition. Additionally, be sure to provide a detailed point-by-point response to the comments of the reviewers. Failure to do so will delay consideration of the revised manuscript.Prior to publication we require copyright releases signed by all authors. Our Authors Assurances and Assignment of Copyright form. can be downloaded from http:/www.aacc.org/ccj/auth_assure02.pdf. Please note that all authors must sign both sections of the form. (a signature on the lower section means that all conflicts of interest have been disclosed even if there are none). Send the completed form. to us by FAX (434-979-7599).Sincerely,Dr. xxx nesleyAssociate EditorP.S. You will find your revised manuscript. can be uploaded in your Submit a Revision queue at http:/submit.cli nchem.org. Please do not beg in the submissi on of your revised manuscript. until you are ready to submit the entire manuscript. A checklist regarding requirementsforsubmissioncanbefoundathttp:/www.aacc.org/ccj/manuscript_check02.pdf. Figures must be uploaded as Image Files in .tif or .eps files at 6